newYou can listen to Fox’s news articles!
They may have gained popularity with diabetes Weight lossHowever, GLP-1 drugs such as Ozempic and Wegovy are associated with ever-growing health benefits.
In fact, some doctors, including Dr. Terry Dubrough, a plastic surgeon based in Newport Beach, California, and television personality, recommend that everyone take a lower dose every day, even if they don’t need to lose weight.
Dubrow spoke about the benefits of “mineralizing” these drugs on camera with Fox News Digital. (See the video at the top of this article.)
How GLP-1 works
GLP-1 receptor agonists It works by mimicking a hormone called peptide-1, such as glucagon, which is released from the intestines after meals.
This drug helps regulate blood sugar levels, slow stomach emptying, reduce appetite, and also Heart disease.
Dr. Terry Dubrough, a plastic surgeon based in Newport Beach, California, and television personality, recommends that everyone take a low dose of GLP-1, even if they don’t need to lose weight. (Terry Dubrough)
“Sugar is the enemy, and these drugs affect the sugar in your blood,” Dubrow told Fox News Digital. “They affect the way insulin reacts.”
GLP-1 allows insulin to transfer glucose (sugar) from the bloodstream to somatic cells, and uses it for energy and store it, doctors said. Drugs also prevent inflammation and prevent sugar from causing in blood vessels, nerves and organs.
“Next Ozempic” aims to provide 30% weight loss with fewer side effects
“I don’t think anyone would argue that if there was a way to manipulate the amount of sugar and inflammation that is exposed to your body, it’s something we want to lean in. That’s exactly what these drugs do.”
In addition to regulating and triggering blood glucose Weight lossGLP-1 is approved to reduce the risk of cardiovascular events and kidney disease in certain patients.
“I have never seen drugs on such a rapid path to approval in medical history.”
“Even if you’re not overweight, using these GLP-1 drugs can help you minimize and prevent recurrent heart attacks,” says Dubrow.
Semaglutide was also recently approved for mash (metabolic dysfunction-associated steatohepatitis), an inflammatory form of fatty liver disease.
Dubrow spoke on camera on Fox News Digital about the benefits of GLP-1 drugs. (Fox News Digital)
GLP-1 is also being studied for its potential Benefits of cognition Parkinson’s disease patient.
“I have never seen drugs on the rapid path to approval in medical history,” Dubrow said.
In the case of microdoshing
Along with other experts, Dubrow is advocate for the mega-like, where people take low and stable doses every day, every day, without needing them for diabetes or obesity.
meanwhile Diabetic patients When taking doses that increase every 4 weeks, microdosing is accompanied by using low-level doses that do not rise.
Experts say weight loss is tough with ultra-processed foods that are hiding in almost every diet
The young population of Tiktok is focused on microdegeneration, Dubrow noted.
“I’m obsessed with the concept of microdegeneration,” he said. “I think half the starting dose of diabetes is the way to go, and you probably don’t need it every seven days. Perhaps every ten days, just to adjust the amount of sugar in your blood.”
“Even if you’re not overweight, using these GLP-1 drugs can help you minimize and prevent recurrent heart attacks,” says Dubrow. (istock)
The doctor noted that there are still many unknowns about GLP-1 drugs.
“For a variety of reasons, I’m just thinking about how to use these drugs for different indications,” he said. “We’re learning to use it.”
“I’m obsessed with the concept of microdegeneration.”
Like Botox, I said there’s a bit of Dubrow.Human experiments“For fun.
“We understand that and teach medical experts how to do it. Patients teach them how to use these drugs.”
Potential risks
GLP-1 drugs are associated with several potential risks. The most common is Gastrointestinal problemsnausea and vomiting, etc.
Others have reported increased risk of pancreatitis, muscle loss and thyroid tumors.
“I’ve read all the research on these drugs and I can tell you, it’s very clear that they don’t cause pancreas,” Dubrow said.
Senior Ozempic push? Some doctors say people over the age of 65 should do that
“In fact, if you really look at the populations that use it, pancreatitis is less in those populations.”
However, Dubrow has confirmed that this drug is associated with a very rare increase in risk Medullary Cancer of the thyroid gland.
Dubrow advised that anyone experiencing serious side effects from GLP-1 should talk to a doctor. (istock)
“If you have Family history In the meantime, it’s a contraindication for you who are using these drugs,” he said.
Regarding side effects of the digestive system, doctors have said that drugs slow the digestive tract, but it has been shown that the body adapts to it over time.
“These specific drugs are natural hormones that occur in our small intestine, and we become accustomed to the side effects. They’ll disappear.”
Click here to get the Fox News app
The severity of side effects is related to dose, Dubrow noted.
“Low doses, especially microdose, are truly less prone to constipation, nausea, potential diarrhea and GERD,” he said. “I don’t think these side effects are that important for people who do microdose.”
To combat the risk of muscle loss, Dubrow recommends incorporating increased protein intake and resistance training as core components of your exercise routine.
Those experiencing serious side effects should do so Please consult a doctorhe advised.
Off-label use of GLP-1, such as microdrugs, is common, according to Dubrow. (istock)
Drugmaker weight
When contacted by Fox News Digital, the manufacturer of GLP-1 drugs warned against micro-drugs in the product.
“Lily has no data on the benefits or risks of Zepbound and Munjaro microdegeneration,” said a spokesman for Eli Lilly, the maker of GLP-1 drugs Mounjaro and Zepbunda. “Both automatic injectors and Zepbound vials are approved for disposable use only. Dose splitting or “traces” are not considered by FDA labels. Safety risk. ”
“Off-of-label use of Zepbound and Mounjaro can pose a patient safety risk.”
Novo Nordisk, the manufacturer of Ozempic and Wegovy, said it did not tolerate “misuse” of its products.
“It is important to understand that for Wegovy, only significant doses of used fixed dose pens (0.25, 0.5, 1.0, 1.7, and 2.4 mg) are approved for use and represent genuine FDA-approved medications. “The starting dose for Wegovy® is 0.25 mg once a week, and the dose gradually increases every 4 weeks. Patients should work together.” Doctor; Medical professional To choose 1.7 mg or 2.4 mg as a maintenance dose. ”
Cheap Ozempic imitations are becoming more popular
“It is also important to note that the real Wegovy injectable pen is designed as a single-use pen, and the dose is already set and should not be altered or tampered, and the pen must be disposed of after one use.”
“Ozempic is a multipurpose pen with one pen and multiple needles,” the spokesman added.
Access GLP-1
Dubrow said he is not worried about supply issues amid growing popularity of the GLP-1. Pharmaceutical Company They have the resources to “scales up” to meet demand.
Off-label use of GLP-1, such as microdrugs, is common, according to Dubrow.
Click here to sign up for our health newsletter
The doctor warned against purchasing these medications from online marketplaces.
“It’s hard to find online from the pharmacies that formulate these drugs, because they’re essentially cheating. That’s illegal. They don’t allow it,” he warned.
“These drugs are natural hormones that occur in our small intestine, and get used to the side effects.”
“So, if you get it from a rogue pharmacy that isn’t allowed to do it or is willing to bending the rules, what is it? You don’t know what you’re getting.”
“It could be a disharmony and weird version with or not effective side effects.”
Looking ahead
There are a few Next Generation Drugs In developing a combination of multiple hormonal pathways, Dubrow said.
“I’ll predict within five years, we have pills… designed to manipulate hunger and insulin resistance,” he predicted.
Visit us for more health articles www.foxnews.com/health
Overall, Dubrow says the GLP-1 will “stay here.”
“They’re just getting better and we’re going to learn how to use them in a more appropriate and clinically effective way,” he said. “Tighten your seat belts. If you’re not on them now, you’ll be later.”
